Li Kunying, Lian Taomei, Wang Zhenjing, Zhang Zhengxun, Wang Wenbo, Qian Jiaping
Department of Endoscopy, Henan Provincial Chest Hospital, Zhengzhou, Henan, China.
First Department of Tuberculosis, Henan Provincial Chest Hospital, Zhengzhou, Henan, China.
Front Surg. 2025 Aug 7;12:1642449. doi: 10.3389/fsurg.2025.1642449. eCollection 2025.
To explore the short-term prognosis, mid- and long-term clinical follow-up of bronchoscopic intervention therapy (BIT) combined with bronchial artery embolization (BAE) in the treatment of massive hemoptysis.
Patients with massive hemoptysis who received BAE (BAE group) or BAE combined with BIT (BAE & BIT group) based on standard clinical treatment were included retrospectively, during June 2022 and March 2023. The short-term prognosis assessed by the therapeutic response, hemoptysis recurrence rates at 1-month post-surgery, and postoperative complications were compared. Mid- and long-term clinical follow-up data were collected.
Data were collected from 136 patients. There were 68 patients (aged 21-60 years, 31 males) received BAE & BIT, and 68 patients (aged 20-59 years, 36 males) received BAE were matched. After surgery, the immediate response rate and total response rate in BIT & BAE group were significantly higher than those in BAE group, while comparable hemoptysis recurrence rates at 1-month post-surgery. Patients in BIT & BAE group had significantly lower rates of postoperative complications, including obstructive pneumonia lung consolidation, and atelectasis, compared to those in BAEgroup. No death in the BIT & BAE group, while the BAE group experienced 3 intraoperative deaths and 4 cases requiring conversion to surgical intervention. No recurrence was observed during the mid-term and long-term follow-up.
Compared to BAE alone, BIT combined with BAT may offer better short-term prognosis, including higher response rate, lower rates of postoperative complications and mortality, in the management of massive hemoptysis, with a good mid- and long-term therapeutic effects.
探讨支气管镜介入治疗（BIT）联合支气管动脉栓塞术（BAE）治疗大咯血的短期预后及中长期临床随访情况。
回顾性纳入2022年6月至2023年3月期间基于标准临床治疗接受BAE（BAE组）或BAE联合BIT（BAE&BIT组）的大咯血患者。比较两组的治疗反应、术后1个月咯血复发率及术后并发症等评估的短期预后。收集中长期临床随访数据。
共收集136例患者数据。匹配68例接受BAE&BIT的患者（年龄21 - 60岁，男性31例）和68例接受BAE的患者（年龄20 - 59岁，男性36例）。术后，BIT&BAE组的即时反应率和总反应率显著高于BAE组，而术后1个月的咯血复发率相当。与BAE组相比，BIT&BAE组患者的术后并发症发生率显著更低，包括阻塞性肺炎肺实变和肺不张。BIT&BAE组无死亡病例，而BAE组有3例术中死亡，4例需转为手术干预。中长期随访期间未观察到复发。
与单纯BAE相比，BIT联合BAT在大咯血治疗中可能具有更好的短期预后，包括更高的反应率、更低的术后并发症发生率和死亡率，且中长期治疗效果良好。
